Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025

Celldex (CLDX) announced positive Phase 2 data for barzolvolimab in chronic spontaneous urticaria (CSU), demonstrating sustained complete responses and improved quality of life 7 months post-treatment; 41% of patients on the 150mg Q4W dose achieved complete response (UAS7=0) and 48% reported no impact on quality of life (DLQI=0/1) at 76 weeks. The drug, which targets mast cells, showed a favorable safety profile and is currently in Phase 3 trials for CSU, with enrollment ongoing, suggesting potential as a transformative treatment option.

Analysis

Celldex Therapeutics (NASDAQ:CLDX) has announced compelling new long-term efficacy and safety data from its Phase 2 study of barzolvolimab in chronic spontaneous urticaria (CSU), showing profound and sustained clinical benefits seven months after treatment completion. At 76 weeks, 41% of patients treated with barzolvolimab 150 mg Q4W maintained a complete response (UAS7=0, indicating no itch/hives), and 48% reported their CSU no longer impacted their quality of life (DLQI=0/1). These results extend earlier findings where up to 71% of patients achieved complete response during the 52-week active therapy phase. Barzolvolimab, which targets the KIT receptor on mast cells, demonstrated rapid improvements from baseline in UAS7 scores (e.g., -20.42 for 150 mg Q4W at Week 76) and efficacy was consistent regardless of prior omalizumab experience. The drug exhibited a well-tolerated safety profile over 76 weeks, with common adverse events being Grade 1, mechanism-related (KIT inhibition), and reversible, such as transient neutropenia and mild, reversible hair/skin pigmentation changes. With enrollment ongoing for its global Phase 3 CSU program (EMBARQ-CSU1 and EMBARQ-CSU2), Celldex is positioning barzolvolimab as a potentially transformative therapy, addressing the root cause of CSU. This potential is underscored by physician commentary highlighting the "unprecedented" sustained complete response post-therapy and the drug demonstrating "best in disease data" across multiple endpoints.

Key Decisions for Investors

• The robust and sustained efficacy from the Phase 2 barzolvolimab study, particularly the high rates of complete response and improved quality of life seven months post-dosing, significantly strengthens the drug's clinical profile and potential market positioning in CSU.
• Investors should closely monitor the progress and subsequent data readouts from the ongoing pivotal Phase 3 trials (EMBARQ-CSU1 and EMBARQ-CSU2), as these will be key catalysts for Celldex and critical for regulatory submission.
• While the data are highly encouraging and suggest transformative potential, it is prudent to remain aware of the inherent risks associated with late-stage clinical development, the regulatory approval pathway, and the future competitive landscape for CSU treatments.